Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Cancer Prev Res (Phila). 2013 Aug 20;6(10):1074–1083. doi: 10.1158/1940-6207.CAPR-13-0157

Fig. 5. VEDT, alone and in combination with gemcitabine (Gem), induces cell cycle arrest and inhibits survival pathway in tumors of KPC mice.

Fig. 5

A, Western blot of p27Kip1 and p21Cip1 in tumors of drug-treated KPC mice. Gemcitabine, VEDT, and gemcitabine + VEDT treatment induced cell cycle inhibitor proteins p21Cip1and p27kip-1 in pancreatic tumor tissues (n = 5). B, Western blots of pAKT, pMEK, and pERK in tumors of KPC mice (n = 5). A significant inhibition of pAKT and pMEK (aP<0.001) was noted in VEDT- and gemcitabine + VEDT-treated mice compared to vehicle treatment. Gemcitabine (bP < 0.05), VEDT (aP < 0.001), and gemcitabine + VEDT (aP < 0.001) significantly inhibited pERK expression in tumor tissues of KPC mice (right). All statistical analyses were performed using ANOVA with Duncan test.